Table 3.
Clinical characteristics of 86 TED patients compared by TPOAb and TGAb.
| Clinical characteristics | TPOAb (-) and TGAb (-) | TPOAb (+) and /or TGAb (+) | P-value | ||
|---|---|---|---|---|---|
| TPOAb (+) and TGAb (-) | TPOAb (-) and TGAb (+) | TPOAb (+) and TGAb (+) | |||
| N | 52 | 14 | 6 | 14 | |
| CAS ≥ 3 points (n, %) | 16 (80.0) | 0 (0.0) | 2 (33.3) | 2 (14.3) | 0.077 |
| CAS | 1.73 ± 1.36 | 1.07 ± 0.73 | 2.00 ± 2.10 | 1.71 ± 0.91 | 0.321 |
| Spontaneous orbital pain (n, %) | 4 (7.7) | 0 (0.0) | 1 (16.7) | 1 (7.1) | 0.581 |
| Gaze-evoked orbital pain (n, %) | 5 (9.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.325 |
| Eyelid erythema (n, %) | 2 (3.8) | 0 (0.0) | 2 (33.3) *# | 5 (35.5) *# | 0.001 |
| Eyelid edema (n, %) | 38 (73.1) | 11 (78.6) | 3 (50.0) | 10 (71.4) | 0.620 |
| Conjunctival redness (n, %) | 23 (44.2) | 2 (14.3) | 2 (33.3) | 5 (35.7) | 0.231 |
| Chemosis (n, %) | 7 (13.5) | 1 (7.1) | 2 (33.3) | 1 (7.1) | 0.378 |
| Caruncle edema (n, %) | 11 (21.2) | 1 (7.1) | 2 (33.3) | 2 (14.3) | 0.481 |
| Bilateral (n, %) | 45 (86.5) | 12 (85.7) | 4 (66.7) | 13 (92.9) | 0.488 |
| Eyelid retraction (n, %) | 34 (65.4) | 6 (42.9) | 5 (83.3) | 7 (50.0) | 0.231 |
| Proptosis (n, %) | 41 (78.8) | 13 (92.9) | 4 (66.7) | 14 (100) | 0.124 |
| EUGOGO classification of severity of TED | |||||
| Mild (n, %) | 14 (26.9) | 3 (21.4) | 1 (16.7) | 2 (14.3) | 0.462 |
| Moderate-to-severe (n, %) | 37 (71.2) | 10 (71.4) | 4 (66.7) | 12 (85.7) | |
| Sight-threatening (n, %) | 1 (1.9) | 1 (7.1) | 1 (16.7) | 0 (0.0) | |
| DON (n, %) | 1 (1.9) | 1 (7.1) | 1 (16.7) | 0 (0.0) | 0.209 |
| Lagophthalmos (n, %) | 12 (23.1) | 4 (28.6) | 4 (66.7) | 0 (0.0) *† | 0.013 |
| Exophthalmos (mm) | 18.94 ± 3.60 | 19.14 ± 1.96 | 19.50 ± 4.93 | 20.21 ± 2.19 | 0.641 |
| Gorman diplopia score | 2.0 (0.0, 3.0) | 1.0 (0.0, 3.0) | 0.5 (0.0, 1.5) | 1.0 (0.0, 2.0) | 0.205 |
| Thyroid status | 0.073 | ||||
| Euthyroidism (n, %) | 36 (69.2) | 10 (71.4) | 4 (66.7) | 8 (57.1) | |
| Hyperthyroidism (n, %) | 12 (23.1) | 4 (28.6) | 1 (16.7) | 1 (7.1) | |
| Hypothyroidism (n, %) | 4 (7.7) | 0 (0.0) | 1 (16.7) | 5 (35.7) | |
| FT3 (pmol/L) | 5.13 ± 0.61 | 5.25 ± 1.23 | 5.33 ± 0.85 | 5.14 ± 0.73 | 0.766 |
| FT4 (pmol/L) | 11.64 ± 2.24 | 11.45 ± 1.98 | 12.32 ± 4.05 | 11.63 ± 1.59 | 0.889 |
| TSH (mIU/L) | 1.54 (0.68, 2.79) | 2.59 (2.04, 3.29) | 2.26 (1.31, 10.04) | 2.50 (1.49, 6.43) | 0.059 |
| TRAb (IU/ml) | 1.19 ± 0.35 | 0.96 ± 0.20 | 1.23 ± 0.36 | 1.29 ± 0.37 | 0.052 |
| TG (ng/ml) | 11.02 (4.51, 20.02) | 7.31 (0.74, 17.68) | 0.10 (0.05, 0.95) *# | 0.72 (0.25, 4.05) * | < 0.001 |
*, #, and † indicated P < 0.05 for comparisons TPOAb (-) and TGAb (-) group, TPOAb (+) and TGAb (-) group, and TPOAb (-) and TGAb (+) group. ※ represent that the contrast differences among the 4 groups of TED patients are statistically significant. Abbreviations: TED denotes thyroid eye disease; FT3 Free Triiodothyronine; FT4 Free Thyroxine; TRAb thyrotrophin receptor antibody; TGAb thyroid globulin antibodies; TPOAb thyroid peroxidase antibodies; CAS clinical activity score; TSH Thyroid Stimulating Hormone; DON dysthyroid optic neuropathy; TG thyroglobulin.